世界の二重特異性抗体（BsAb）市場

本レポートは、世界の二重特異性抗体（BsAb）市場の概要と市場動向の分析を提供します。2022年から2024年までの基準年データにおける世界収益（百万ドル）と、2025年から2030年までの予測期間における推定データが含まれています。

レポートの内容

•  抗がん療法における新たなアプローチである二重特異性抗体（bsAb）の世界市場分析
•  2022年から2025年までの過去の収益（売上データ）と2030年までのCAGR予測を含む、世界市場動向の分析
•  投与経路、作用機序、用途、エンドユーザー、地域別の市場シェア分析を伴う、世界市場の現在の市場規模と収益見通しの推定
•  市場動向、技術進歩、規制、見通し、マクロ経済変数の影響に関する事実と数値
•  ポーターの5フォースモデルおよびグローバルサプライチェーン分析から得られた洞察
•  主要な取得済みおよび公開済み特許を特集した特許レビュー
•  企業の市場シェアとランキング、製品マッピング、戦略的イニシアチブ、M&A活動、ベンチャー資金調達の見通しを含む業界構造の分析
•  消費者の意識、主要企業のESGリスク評価と実践に重点を置いた、サステナビリティ動向とESGの発展の概要
•  主要企業のプロファイル世界をリードする企業

本レポートは、二重特異性抗体（BsAb）の世界市場の概要を提供します。2024年の基準年の世界収益（百万ドル）、2025年の推定収益、および2026年から2030年末までの予測期間のデータが含まれています。また、本レポートは、投与経路、作用機序、用途、エンドユーザー別に、二重特異性抗体の世界市場を分析およびセグメント化しています。さらに、主要な新興トレンドと潜在的な成長要因に関する洞察も提供します。本調査は、静脈内（IV）、皮下（SC）、およびその他の投与経路に焦点を当てています。市場は、用途別に、がん治療、自己免疫疾患、およびその他のセグメント化されています。作用機序別には、T細胞リダイレクション二重特異性抗体、二重抗原腫瘍標的二重特異性抗体、およびその他のセグメント化されています。エンドユーザー別には、製薬会社およびバイオテクノロジー企業、受託研究機関（CRO）、および学術研究機関に分類されています。

Report Highlights

This report provides an overview of the global bispecific antibodies market and analyzes market trends. It includes global revenue ($ million) for the base year data for 2022- 2024 and estimated data for the forecast period from 2025 through 2030.

Report Includes

• Analysis of the global market for bispecific antibodies (bsAbs), a novel approach to anticancer therapy
• Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects for the global market, accompanied by a market share analysis by route of administration, mechanisms of action, application, end user, and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impact of macroeconomic variables
• Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
• Patent review, featuring key granted and published patents
• Analysis of the industry structure, including companies’ market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Profiles of the leading global companies

Report Scope

The report provides an overview of the global market for bispecific antibodies. It includes global revenue ($ million) for the base year of 2024, estimated revenue for 2025, and data for the forecast period 2026 through the end of 2030. The report also analyzes and segments the global bispecific antibodies market by route of administration, mechanisms of action, application, and end user. It also provides insights into key emerging trends and potential growth drivers. The study focuses on the route of administration, including intravenous (IV), subcutaneous (SC), and other. The market is segmented by application into cancer treatment, autoimmune disorders, and other. By mechanism of action, the market focuses on T-cell redirecting bispecific antibodies, dual-antigen tumor-targeting bispecific antibodies, and other. The market is segmented by end users as pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic and research institutions.

The report provides a comprehensive regional analysis covering North America, Europe, Asia-Pacific, South America, the Middle East, and Africa. It evaluates market dynamics, including drivers, challenges, and emerging trends, while highlighting innovations in product and performance enhancements. The study concludes with an analysis of major companies and their offerings.

Table of Contents

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
Future Outlook
Macroeconomic Factors Analysis
Demographic Factors
Global Economic Growth
Impact of U.S. Tariffs
Impact of the Ukraine-Russia War on the Bispecific Antibodies Industry
Porter’s Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Global Burden of Cancer
R&D Investment by Large Pharmaceutical and Biotechnology Companies
Growing Adoption of Immuno-Oncology Therapies in Standard Treatment Pathways
Market Restraints
High Treatment Cost and Pricing Pressure
Shortage of Oncology Professionals
Stringent Government Regulations
Market Opportunities
Development of Bispecific Antibodies for Solid Tumors
Expansion in Emerging Markets
Chapter 4 Regulatory Landscape
Overview
U.S.
Europe
Asia-Pacific
Chapter 5 Emerging Technologies
Overview
Newest Technologies/Trends
Next-Generation Bispecific Antibody Formats with Improved Stability and Half-Life
Subcutaneous and Outpatient Administration Optimized Bispecific Antibodies
AI-Assisted Antibody Design and Target Selection
Combination Regimens with Immune Checkpoint Inhibitors or Targeted Therapies
Conditional Activation and Tumor-Restricted Bispecific Designs
Chapter 6 Market Segment Analysis
Segmentation Breakdown
Global Bispecific Antibodies Market, by Route of Administration
Key Takeaways
Intravenous (IV)
Subcutaneous (SC)
Others
Global Bispecific Antibodies Market, by Application
Key Takeaways
Cancer Treatment
Autoimmune Disorders
Others
Global Bispecific Antibodies Market, by Mechanisms of Action
Key Takeaways
T-cell Redirecting Bispecific Antibodies
Dual-Antigen Tumor-targeting Bispecific Antibodies
Others
Global Bispecific Antibodies Market, by End User
Key Takeaways
Pharmaceutical and Biotechnology Companies
CROs
Academic and Research Institutions
Geographic Breakdown
Global Bispecific Antibodies Market, by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America
Chapter 7 Clinical Trial and Patent Analyses
Clinical Trial Analysis
Key Takeaway
Patent Analysis
Key Takeaways
Patents, by Jurisdiction
Patents, by Applicants
Chapter 8 Competitive Intelligence
Key Takeaways
Strategic Analysis
Chapter 9 Appendix
Research Methodology
Sources
Acronyms
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JAZZ PHARMACEUTICALS INC.
JOHNSON & JOHNSON
LILLY USA LLC.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
Emerging Start-ups/ Market Disruptors

List of Tables

Summary Table : Global Market for Bispecific Antibodies, by Region, Through 2030
Table 1 : Current Health Expenditure, by Select Countries/Regions, 2021-2023
Table 2 : Global Market for Bispecific Antibodies, by Route of Administration, Through 2030
Table 3 : Global Market for Intravenous (IV) Route of Administration, by Region, Through 2030
Table 4 : Global Market for Subcutaneous (SC) Route of Administration, by Region, Through 2030
Table 5 : Global Market for Other Route of Administration, by Region, Through 2030
Table 6 : Global Market for Bispecific Antibodies, by Application, Through 2030
Table 7 : Global Market for Cancer Treatment, by Region, Through 2030
Table 8 : Global Market for Autoimmune Disorder Treatments, by Region, Through 2030
Table 9 : Global Market for Other Applications, by Region, Through 2030
Table 10 : Global Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
Table 11 : Global Market for T-cell Redirecting Bispecific Antibodies, by Region, Through 2030
Table 12 : Global Market for Dual-Antigen Tumor-targeting Bispecific Antibodies, by Region, Through 2030
Table 13 : Global Market for Other Mechanisms of Action, by Region, Through 2030
Table 14 : Global Market for Bispecific Antibodies Market, by End User, Through 2030
Table 15 : Global Market for Pharmaceutical and Biotechnology Companies, by Region, Through 2030
Table 16 : Global Market for Contract Research Organizations (CROs), by Region, Through 2030
Table 17 : Global Market for Academic and Research Institutions, by Region, Through 2030
Table 18 : Global Market for Bispecific Antibodies, by Region, Through 2030
Table 19 : North American Market for Bispecific Antibodies, by Country, Through 2030
Table 20 : North American Market for Bispecific Antibodies, by Route of Administration, Through 2030
Table 21 : North American Market for Bispecific Antibodies, by Application, Through 2030
Table 22 : North American Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
Table 23 : North American Market for Bispecific Antibodies, by End User, Through 2030
Table 24 : European Market for Bispecific Antibodies, by Country, Through 2030
Table 25 : European Market for Bispecific Antibodies, by Route of Administration, Through 2030
Table 26 : European Market for Bispecific Antibodies, by Application, Through 2030
Table 27 : European Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
Table 28 : European Market for Bispecific Antibodies, by End User, Through 2030
Table 29 : Asia-Pacific Market for Bispecific Antibodies, by Country, Through 2030
Table 30 : Asia-Pacific Market for Bispecific Antibodies, by Route of Administration, Through 2030
Table 31 : Asia-Pacific Market for Bispecific Antibodies, by Application, Through 2030
Table 32 : Asia-Pacific Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
Table 33 : Asia-Pacific Market for Bispecific Antibodies, by End User, Through 2030
Table 34 : MEA Market for Bispecific Antibodies, by Sub-Region, Through 2030
Table 35 : MEA Market for Bispecific Antibodies, by Route of Administration, Through 2030
Table 36 : MEA Market for Bispecific Antibodies, by Application, Through 2030
Table 37 : MEA Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
Table 38 : MEA Market for Bispecific Antibodies, by End User, Through 2030
Table 39 : South American Market for Bispecific Antibodies, by Country, Through 2030
Table 40 : South American Market for Bispecific Antibodies, by Route of Administration, Through 2030
Table 41 : South American Market for Bispecific Antibodies, by Application, Through 2030
Table 42 : South American Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
Table 43 : South American Market for Bispecific Antibodies, by End User, Through 2030
Table 44 : Selected Bispecific Antibodies Clinical Trials Studies, 2025
Table 45 : Patents Granted for Bispecific Antibodies, by Applicants, January 2022-December 2025
Table 46 : Strategic Initiatives in the Global Bispecific Antibodies Market, 2025
Table 47 : Information Sources in This Report
Table 48 : Abbreviations Used in the Global Bispecific Antibodies Market
Table 49 : AbbVie Inc.: Company Snapshot
Table 50 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 51 : AbbVie Inc.: Product Portfolio
Table 52 : AbbVie Inc.: News/Key Developments, 2023-2025
Table 53 : Amgen Inc.: Company Snapshot
Table 54 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 55 : Amgen Inc.: Product Portfolio
Table 56 : Amgen Inc.: News/Key Developments, 2025
Table 57 : AstraZeneca: Company Snapshot
Table 58 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 59 : AstraZeneca: Product Portfolio
Table 60 : AstraZeneca: News/Recent Developments, 2022-2023
Table 61 : Bristol-Myers Squibb Co.: Company Snapshot
Table 62 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 63 : Bristol-Myers Squibb Co.: Product Portfolio
Table 64 : Bristol-Myers Squibb Co.: News/Key Developments, 2025
Table 65 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 66 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 67 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 68 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
Table 69 : Jazz Pharmaceuticals Inc.: Company Snapshot
Table 70 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 71 : Jazz Pharmaceuticals Inc.: Product Portfolio
Table 72 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2024-2025
Table 73 : Johnson & Johnson: Company Snapshot
Table 74 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 75 : Johnson & Johnson: Product Portfolio
Table 76 : Johnson & Johnson: News/Key Developments, 2022−2025
Table 77 : Lilly USA LLC.: Company Snapshot
Table 78 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 79 : Lilly USA LLC.: Product Portfolio
Table 80 : Pfizer Inc.: Company Snapshot
Table 81 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 82 : Pfizer Inc.: Product Portfolio
Table 83 : Pfizer Inc.: News/Key Developments, 2023-2025
Table 84 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 85 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 86 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 87 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2024-2025
Table 88 : List of a Few Emerging Startups

List of Figures

Summary Figure : Global Market Shares of Bispecific Antibodies, by Region, 2024
Figure 1 : Porter’s Five Forces Analysis of the Bispecific Antibodies Market
Figure 2 : Bispecific Antibodies Market Dynamics
Figure 3 : Estimated New Cancer Cases and Deaths in the U.S., 2024
Figure 4 : Company R&D Expenditure Shares, by Function, 2022
Figure 5 : Global Market Shares of Bispecific Antibodies, by Route of Administration, 2024
Figure 6 : Global Market Shares of Bispecific Antibodies, by Application, 2024
Figure 7 : Global Market Shares of Bispecific Antibodies Market, by Mechanisms of Action, 2024
Figure 8 : Global Market Shares of Bispecific Antibodies Market, by End User, 2024
Figure 9 : Global Market Shares of Bispecific Antibodies, by Region, 2024
Figure 10 : North American Market Shares of Bispecific Antibodies, by Country, 2024
Figure 11 : European Market Shares of Bispecific Antibodies, by Country, 2024
Figure 12 : Asia-Pacific Market Shares of Bispecific Antibodies, by Country, 2024
Figure 13 : MEA Market Shares of Bispecific Antibodies, by Sub-Region, 2024
Figure 14 : South American Market Shares of Bispecific Antibodies, by Country, 2024
Figure 15 : Patents Granted for Bispecific Antibodies, by Year, January 2022–December 2025
Figure 16 : Patents Granted for Bispecific Antibodies, by Jurisdiction, January 2022-December 2025
Figure 17 : Global Market Shares of the Bispecific Antibodies Industry, by Companies, 2024
Figure 18 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 19 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 20 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 21 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 22 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 23 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 24 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 25 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 26 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 27 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 28 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 29 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 30 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
Figure 31 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
Figure 32 : Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
Figure 33 : Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
Figure 34 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 35 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 36 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024